What the Evidence Actually Shows
Cannabis science beyond the headlines. The endocannabinoid system, cannabinoid pharmacology, clinical trial results, drug interactions, safety data, and the lab testing crisis — sourced from NASEM, FDA documentation, and peer-reviewed research. Not medical advice. Not product recommendations. Just what the data says.
The Gap Between Marketing and Evidence
CBN is marketed as a sleep aid, but a 2021 review found zero clinical trials supporting the claim. Delta-8 products contain 25–35% unidentified byproducts. The entourage effect has never been demonstrated through direct cannabinoid receptor modulation. And patients are refusing proven chemotherapy based on petri-dish cancer studies that have never been replicated in humans.
Meanwhile, genuine evidence exists — for chronic neuropathic pain (NNT 3.6), for intractable epilepsy (Epidiolex), for chemotherapy nausea. The endocannabinoid system is one of the most important signaling networks in mammalian physiology. The science is real. It just needs an honest accounting.
We use the NASEM 2017 framework — the gold standard for evaluating cannabis medical claims. Conclusive, substantial, moderate, limited, or insufficient.
Every major claim cites the researcher, year, journal, and study design. No anonymous assertions. If the evidence is weak, we say so.
We distinguish what clinical trials show from what product labels claim. The gap is often enormous — and that gap puts consumers at risk.
CannaScience is an educational resource, not a substitute for professional medical guidance. Always consult a healthcare provider about your specific situation.
Featured Deep Dives
The Major Cannabinoids
For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org